Plain language summary of a review on omalizumab for treating chronic spontaneous urticaria

This Plain Language Summary of Publication article (PLSP) from Immunotherapy, highlights key published information about omalizumab and its use in chronic spontaneous urticaria (CSU). CSU is a long-term skin condition causing itchy hives and swelling for over six weeks without a clear trigger, often affecting daily life. Many people with CSU are treated with omalizumab (Xolair^®), a medicine that works by blocking a blood protein called IgE.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status’ and was published in Dermatology and Therapy.

Visit SpringerNature Link using the link to read the original article.

• Allergies
• autoimmunity
• dermatology
• immunotherapy
• lay language summary
• omalizumab
• plain language summary